HOWARD WEINER to Alemtuzumab
This is a "connection" page, showing publications HOWARD WEINER has written about Alemtuzumab.
Connection Strength
0.216
-
Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study. Mult Scler. 2019 10; 25(12):1605-1617.
Score: 0.140
-
Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon ?-1a in MS. Neurology. 2016 Oct 04; 87(14):1464-1472.
Score: 0.030
-
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet. 2012 Nov 24; 380(9856):1829-39.
Score: 0.023
-
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet. 2012 Nov 24; 380(9856):1819-28.
Score: 0.023